SUSY vertex algebras and supercurves

This article is a continuation of math.QA/0603633 Given a strongly conformal SUSY vertex algebra V and a supercurve X we construct a vector bundle V_X on X, the fiber of which, is isomorphic to V. Moreover, the state-field correspondence of V canonically gives rise to (local) sections of these vector bundles. We also define chiral algebras on any supercurve X, and show that the vector bundle V_X, corresponding to a SUSY vertex algebra, carries the structure of a chiral algebra.Comment: 50 page

Clinical features of post-COVID-19 period. Results of the international register “Dynamic analysis of comorbidities in SARS-CoV-2 survivors (AKTIV SARS-CoV-2)”. Data from 6-month follow-up

Aim. To study the clinical course specifics of coronavirus disease 2019 (COVID-19) and comorbid conditions in COVID-19 survivors 3, 6, 12 months after recovery in the Eurasian region according to the AKTIV register. Material and methods.The AKTIV register was created at the initiative of the Eurasian Association of Therapists. The AKTIV register is divided into 2 parts: AKTIV 1 and AKTIV 2. The AKTIV 1 register currently includes 6300 patients, while in AKTIV 2 — 2770. Patients diagnosed with COVID-19 receiving in- and outpatient treatment have been anonymously included on the registry. The following 7 countries participated in the register: Russian Federation, Republic of Armenia, Republic of Belarus, Republic of Kazakhstan, Kyrgyz Republic, Republic of Moldova, Republic of Uzbekistan. This closed multicenter register with two nonoverlapping branches (in- and outpatient branch) provides 6 visits: 3 in-person visits during the acute period and 3 telephone calls after 3, 6, 12 months. Subject recruitment lasted from June 29, 2020 to October 29, 2020. Register will end on October 29, 2022. A total of 9 fragmentary analyzes of the registry data are planned. This fragment of the study presents the results of the post-hospitalization period in COVID-19 survivors after 3 and 6 months. Results. According to the AKTIV register, patients after COVID-19 are characterized by long-term persistent symptoms and frequent seeking for unscheduled medical care, including rehospitalizations. The most common causes of unplanned medical care are uncontrolled hypertension (HTN) and chronic coronary artery disease (CAD) and/or decompensated type 2 diabetes (T2D). During 3- and 6-month follow-up after hospitalization, 5,6% and 6,4% of patients were diagnosed with other diseases, which were more often presented by HTN, T2D, and CAD. The mortality rate of patients in the post-hospitalization period was 1,9% in the first 3 months and 0,2% for 4-6 months. The highest mortality rate was observed in the first 3 months in the group of patients with class II-IV heart failure, as well as in patients with cardiovascular diseases and cancer. In the pattern of death causes in the post-hospitalization period, following cardiovascular causes prevailed (31,8%): acute coronary syndrome, stroke, acute heart failure. Conclusion. According to the AKTIV register, the health status of patients after COVID-19 in a serious challenge for healthcare system, which requires planning adequate health system capacity to provide care to patients with COVID-19 in both acute and post-hospitalization period

Can grafting of an octapeptide improve the structure of a de novo protein?

Structural properties and conformational stability of de novo proteins – albebetin and albeferon (albebetin with a grafted interferon fragment) – were studied by means of CD spectroscopy, gel filtration and urea-induced unfolding. The results allow us to conclude that albebetin possesses the properties of the molten globule state. Grafting of the octapeptide to the N-terminus of this de novo protein affects its structure. We show here that albeferon maintains a secondary structure content of albebetin; it becomes more compact and much more stable toward urea-induced unfolding as compared to albebetin and even possesses some weak tertiary structure (at least around Tyr7). This means that the structure of the artificial protein albebetin can be improved by a simple procedure of octapeptide grafting to its N-terminus

Results and analysis of the application of a consistent targeted therapy in patients with metastatic renal cell carcinoma in Moscow (for the period from June 2005 to July 2015)

Background. This article is a personal experience of a sequential targeted therapy of tyrosine kinase inhibitors for the period from June 2005 to July 2015.Objective: evaluation of the results of the consistent application of targeted therapies in Moscow in this period.Materials and methods. A retrospective analysis of cumulative progression-free survival in 220 patients of 354 patients with mRCC were studied. Was used Statistica 10.0 program.Results. This article presents an analysis of the effectiveness of treatment and survival of patients receiving this therapy in cancer institutions Department of Health in Moscow.Conclusion. Using of targeted therapy scheme sunitinib → sorafenib, we see no significant difference sVBP compared with scheme sorafenib → sunitinib with two lines ofsequential therapy tyrosine kinase inhibitors (16.9 and 18.2 months). According to our data total progression-free survival terms as applied to the 1st line of therapy tirosine kinase inhibitors (sunitinib and sorafenib), followed by the appointment pazopanib in the 2nd line (12.5 and 14.4 months) and pazopanib in 1st line followed by the appointment tirazinkinaz inhibitors (sunitinib and sorafenib) in the 2nd line (12.50 and 11.56 months) compared to the preliminary results of a multicenter randomized trial expected SWITCH II also not statistically different